SG Americas Securities LLC reduced its stake in shares of Haemonetics Co. (NYSE:HAE) by 13.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,086 shares of the medical instruments supplier’s stock after selling 966 shares during the period. SG Americas Securities LLC’s holdings in Haemonetics were worth $353,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in HAE. Cubist Systematic Strategies LLC bought a new position in Haemonetics during the 2nd quarter worth $260,000. Parametrica Management Ltd bought a new position in Haemonetics during the 3rd quarter worth $352,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Haemonetics by 430.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,649 shares of the medical instruments supplier’s stock worth $388,000 after purchasing an additional 7,017 shares during the last quarter. AMP Capital Investors Ltd bought a new position in Haemonetics during the 3rd quarter worth $422,000. Finally, Crossmark Global Holdings Inc. bought a new position in Haemonetics during the 3rd quarter worth $442,000. 99.91% of the stock is owned by institutional investors and hedge funds.
Shares of Haemonetics Co. (HAE) opened at $74.41 on Wednesday. The company has a current ratio of 1.82, a quick ratio of 1.33 and a debt-to-equity ratio of 0.14. Haemonetics Co. has a 1-year low of $38.43 and a 1-year high of $74.58. The firm has a market capitalization of $3,949.77, a PE ratio of 40.60, a price-to-earnings-growth ratio of 3.66 and a beta of 0.92.
Haemonetics announced that its Board of Directors has approved a stock buyback plan on Tuesday, February 6th that permits the company to repurchase $260.00 million in shares. This repurchase authorization permits the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.
HAE has been the subject of several analyst reports. Zacks Investment Research raised Haemonetics from a “hold” rating to a “buy” rating and set a $70.00 target price for the company in a research report on Tuesday, January 9th. Morgan Stanley raised Haemonetics from an “equal weight” rating to an “overweight” rating and set a $51.00 target price for the company in a research report on Tuesday, January 2nd. JMP Securities reaffirmed an “outperform” rating and set a $72.00 target price on shares of Haemonetics in a research report on Wednesday, February 7th. Raymond James Financial raised Haemonetics from an “underperform” rating to a “market perform” rating in a research report on Tuesday, January 2nd. Finally, Jefferies Group increased their price target on Haemonetics from $18.00 to $75.00 and gave the stock a “buy” rating in a report on Monday, January 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. Haemonetics presently has an average rating of “Buy” and an average price target of $71.33.
In other news, EVP Michelle L. Basil sold 389 shares of the firm’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $72.23, for a total value of $28,097.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Mark W. Kroll sold 7,118 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $63.00, for a total value of $448,434.00. Following the completion of the sale, the director now owns 33,881 shares of the company’s stock, valued at $2,134,503. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 7,621 shares of company stock valued at $484,766. 1.20% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: “SG Americas Securities LLC Has $353,000 Holdings in Haemonetics Co. (HAE)” was originally posted by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://weekherald.com/2018/03/14/haemonetics-co-hae-holdings-lowered-by-sg-americas-securities-llc.html.
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.